Learn more about Myllia and our powerful CROP-Seq (Perturb-Seq) technology enabling genetic screens for target discovery in primary human cells
We utilise the CROP-Seq (for “CRISPR Droplet Sequencing”, also known as Perturb-Seq) workflow, developed by Myllia’s co-founder Christoph Bock, to map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution, thus effectively establishing a paradigm for next generation CRISPR screens. Our powerful CRISPR-based high-throughput screening approach has broad applications in identifying novel drug targets, elucidating unknown mechanisms of actions of drugs and understanding genetic variants linked to disease risk.
Meet Myllia’s R&D teams focused on CRISPR-based functional genomics screening and computational biology
Our end-to-end high-throughput screening platform for tailor-made CRISPR screens
Myllia has built an end-to-end genetic screening platform in primary human cells and cancer cell lines. We routinely conduct CROP-Seq screens using hundreds of thousands of single cells in one experiment and intend to scale the technology even further.
Learn more about Myllia here: Factsheet | Company Introduction
Our platform features at a glance
- Customized assay development for cellular models, incl. primary cells
- Proprietary guide RNA design algorithms for CRISPRn/i/a
- Proprietary primer panel designs for targeted sequencing (TA-seq)
- Manufacturing of lentiviral guide RNA libraries
- Performance of the pooled CRISPR screens (high-throughput)
- Single-cell library preparation and NGS (WTA and TA-seq)
- Bioinformatic analyses and target deconvolution
Get in touch with Myllia's leadership team and learn more about CROP-Seq - our genetic screening technology in single cells to fast-forward your target discovery projects
Leadership
Scientific Advisory Board
Thomas Moser
CEO
Thomas has extensive experience in financing and corporate development of start-up companies. Since 2018 he is founder and CEO of Myllia Biotechnology (former Aelian Biotechnology) and since 2020 Managing Director of bit.bio discovery. In previous positions, he was founding CEO of Haplogen Genomics, a very successful Austrian life science company sold to Horizon Discovery/UK in 2015, and after the acquisition Vice President Products at Horizon, responsible for gene-engineered cell line products, and Global Head of Corporate Strategy and Compliance. Before he served as Managing Partner at Pontis Capital for 13 years and had several positions in the area of business development, financing and licensing.
Tilmann Buerckstuemmer
CSO
Tilmann is a CRISPR enthusiast since the early days of CRISPR. Originally trained as a biochemist, he joined Haplogen as Principal Scientist and later became their CSO. Following the acquisition by Horizon Discovery, Tilmann served as Director R&D and, later, Head of Innovation where he oversaw Horizon’s technology platform and innovation agenda. In 2018, he co-founded Myllia Biotechnology which focuses on single-cell CRISPR screens. He is also the CEO of bit.bio discovery, a joined venture between Vienna-based Myllia Biotechnology and Cambridge-based bit.bio. Tilmann is passionate about science and enjoys working with multi-disciplinary and multi-national teams.
Christoph Bock
Scientific Advisor
Christoph is a principal investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences. His research focuses on developing high-throughput technologies for biomedical applications. He is also a guest professor at the Medical University of Vienna, scientific coordinator of the Biomedical Sequencing Facility at CeMM, and adjunct group leader for bioinformatics at the Max Planck Institute for Informatics. He has received several research awards, including the Max Planck Society’s Otto Hahn Medal (2009), an ERC Starting Grant (2016-2021), and the Overton Prize of the International Society of Computational Biology (2017).
Luke Gilbert
Scientific Advisor
Luke completed a distinguished postdoctoral stay at the laboratory of Jonathan Weissman, where he performed ground-breaking work on CRISPR interference and activation. He now holds a dual affiliation with the University of California, San Francisco (UCSF) and the esteemed Arc Institute, further solidifying his position as a prominent figure in the field. At UCSF and Arc Institute, Luke’s laboratory is at the forefront of scientific innovation, focusing on the development of new genetic tools to systematically unravel the functions of the genes encoded by the human genome. Their primary mission is to address critical challenges in deadly human cancers, particularly metastasis and drug resistance.
